The new EUROIMMUN Anti-ZnT8 ELISA is an excellent complement to the existing EUROIMMUN portfolio for the detection of autoantibodies in type I diabetes. The combined detection of antibodies against ZnT8, GAD, IA2 and insulin increases the detection rate of diabetes mellitus type I to 98% at disease onset.
Please contact your area ESL sales representatives for more information on EUROIMMUN Anti-ZnT8 ELISA and the EUROIMMUN portfolio for diagnosis of diabetes mellitus type I
|